CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia Clinical Trial

Official title: a Feasibility and Safety Study of Bispecific CD19-CD22 CAR-T Cell in the Treatment of Relapsed or Refractory B-ALL

Status Active, not recruiting

Clinical Trial Summary

This is a single arm, open-label, single center study to determine the safety and efficacy of CD19-CD22 CAR-T cells in patients with CD19+CD22+ Leukemia.

Clinical Trial Description

This is a single arm, open-label, single center study to determine the safety and efficacy of CD19-CD22 CAR-T cells in patients with relapsed or refractory B-ALL. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Follow-up, and Survival Follow-up. The total duration of the study is 2 years from CD19-CD22 CAR-T cell infusion. ;

Related Conditions & MeSH terms

• Leukemia
• Leukemia, Lymphoid
• Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

• NCT number: NCT04034446
• Study type: Interventional
• Source: Institute of Hematology & Blood Diseases Hospital
• Status: Active, not recruiting
• Phase: Early Phase 1
• Start date: September 30, 2019
• Completion date: December 2023